Sennosides A And B (HERRON SENNESOFT tablet blister pack)
What to know about Sennosides A And B — also sold as HERRON SENNESOFT tablet blister pack, AdMed Docu/Senna tablets bottle: uses, side effects, interactions, and safety considerations for people taking it or caring for someone who is.
Sennosides A And B (brand names: HERRON SENNESOFT tablet blister pack, AdMed Docu/Senna tablets bottle) is classified as Low risk (1 risk points) by AllMeds. It is a S2 medication under the TGA in Australia. Stimulant laxative with low risk but potential for dependence and electrolyte disturbance.
Key Takeaways
- TGA Schedule: S2 in Australia
- Risk level: Low (1 points)
- Recommended maximum duration: 7 days
Scheduling and Classification
| Jurisdiction | Classification | Status |
|---|---|---|
| Australia (TGA) | S2 | Not PBS listed |
Risk Profile
Stimulant laxative with low risk but potential for dependence and electrolyte disturbance.
How Sennosides A And B is regulated
Sennosides A And B is overseen by medicines regulators in each country. The rules below explain how it's scheduled, what oversight applies, and what to discuss with your doctor or pharmacist before starting, changing, or stopping this medication.
Australia TGA / PBS / State Schemes
Classified as S2 under the Therapeutic Goods Administration (TGA).
Check this medication against your full medication list
Run a full risk assessment including Sennosides A And B interactions and compliance checks.
Allmeds AI Pharmacist scans interactions, schedules, and risk flags across your entire medication profile in minutes. Free for individuals; team plans for case managers, insurers, and schemes.
Important: This page is general health information, not personal medical advice. If you have questions about your medication — including starting it, stopping it, changing the dose, or combining it with something else — speak with your doctor or pharmacist. For an emergency or suspected overdose, call your local emergency number or poison information service immediately. Information is drawn from regulator and clinical guideline sources (TGA, FDA, MHRA, NICE, PBS, CDC); see our methodology for details.